BIOVENTUS CLASS A INC (BVS)
Sector: Health Care
2026 Annual Meeting Analysis
BIOVENTUS CLASS A INC · Meeting: June 3, 2026
Directors FOR
12
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Director since 2020 with strong relevant medical device industry experience; BVS 3-year price return of +804.2% far exceeds the IHI benchmark threshold of 65pp (actual gap: +810.2pp), so the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
Director since January 2023 with strong finance and governance background; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
Director since October 2021 with extensive medical technology executive experience; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
CEO and director since January 2024, well within the 24-month new-director exemption period relative to the 3-year TSR measurement window; broad medical device leadership background is clearly relevant; no other policy triggers apply.
Director since 2020 with deep medical device and finance experience from Smith & Nephew; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
Director since November 2025, well within the 24-month new-director exemption; strong life sciences strategy and finance background; no other policy triggers apply.
Director since July 2021 with strong healthcare finance and investor relations expertise; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; serves on three public company boards but none individually triggers the overboarding threshold of four or more seats.
Director since January 2022 with relevant regulatory, policy, and medical device experience; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
Director since 2020 with extensive medical device operational and board experience; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
Director since 2020 with deep life sciences venture and board experience; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
Director since 2020 with extensive finance, treasury, and risk management background and designated audit committee financial expert; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
Director since 2020 with over 35 years of life sciences investment and operations experience; BVS 3-year TSR far exceeds the IHI benchmark and the TSR trigger does not apply; no overboarding, attendance, or independence concerns identified.
All twelve director nominees pass the policy screens. Bioventus's 3-year stock return of +804.2% dramatically outperforms the IHI — iShares US Medical Devices ETF benchmark (which returned -6.0% over the same period), producing a +810.2 percentage-point gap that far exceeds the 65pp trigger threshold for a strong-positive-TSR company, so the TSR trigger does not apply to any director. All directors attended at least 75% of meetings, no overboarding issues were identified, all committee members appear to have appropriate independence and expertise, and the board discloses a diversity matrix indicating a range of backgrounds and skills relevant to the company's medical device business.
Say on Pay
✓ FORCEO
Robert E. Claypoole
Total Comp
$4,299,108
Prior Support
N/A
The CEO's total reported compensation of $4,299,108 for 2025 is reasonable for a medical device company in the $660 million market cap range, and the pay mix is appropriately weighted toward variable compensation — approximately 81% of the CEO's total pay came from performance bonuses, stock awards, and stock options rather than fixed salary. The 2025 annual bonus was tied to four objective business measures (revenue, adjusted EBITDA, quality, and cash flow) with a disclosed 94.8% achievement rate, and the company introduced performance stock awards in 2025 that vest based on relative total shareholder return over a three-year period, strengthening the link between pay and long-term shareholder outcomes. The company has a clawback policy adopted in 2023 that complies with Dodd-Frank requirements, and Bioventus's strong stock performance (+804.2% over three years vs. IHI — iShares US Medical Devices ETF at -6.0%) further supports the view that executive incentive pay is aligned with the shareholder experience.
Auditor Ratification
✓ FORAuditor
Grant Thornton LLP
Tenure
N/A
Audit Fees
$2,247,000
Non-Audit Fees
$0
Grant Thornton charged only audit fees ($2,247,000) in fiscal year 2025 with zero non-audit, tax, or other fees, meaning the non-audit fee ratio is 0% — well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire; Bioventus has a market cap of approximately $660 million, and Grant Thornton is a large national firm (top-six in the U.S.) that is appropriate for this size and complexity of company.
Overall Assessment
The 2026 Bioventus annual meeting presents two standard board-recommended proposals — a director slate of twelve nominees and ratification of Grant Thornton as auditor — plus an implicit say-on-pay evaluation based on CEO compensation disclosures in the proxy; there are no stockholder-submitted proposals on the ballot. All proposals pass the applicable policy screens, driven primarily by Bioventus's exceptional three-year stock performance that far exceeds the IHI — iShares US Medical Devices ETF benchmark, a clean auditor fee structure with zero non-audit fees, and a CEO compensation program that appropriately emphasizes variable, performance-linked pay.